Journal: Scientific reports

Article Title: Emerin deficiency drives MCF7 cells to an invasive phenotype.

doi: 10.1038/s41598-024-70752-5

Figure Lengend Snippet: Fig. 9. Reduced emerin expression at the nuclear periphery correlates with breast cancer invasiveness in patients. (A) Representative tissue microarray staining of emerin in 159 patients using emerin polyclonal antibodies (Proteintech, cat# 10351-1-AP) or secondary alone (Vector Lab, cat#: MP-7451). Nuclei are blue, emerin is brown, and arrows denote emerin staining in certain images for reference. As severity of cases increases, there is a visible reduction in emerin expression at the nuclear envelope and more deformed nuclei are present. (B) Quantification of emerin staining on IHC-stained patient samples using 0–3, with 0 having no staining at the nuclear periphery and 3 having complete, dark rim staining. N = 159 total samples, *P < 0.05 compared to normal tissue, one-way ANOVA and Dunnett’s test. Error bars represent standard deviation. (C) Representative tissue microarray staining of emerin in 183 patients using emerin monoclonal antibodies (Leica, NCL-Emerin) or secondary alone (Vector Lab, cat#: MP-7452) using the same samples used in A. Nuclei are blue and emerin is brown. As aggressiveness of cases increases, there is a visible reduction in emerin expression and more deformed nuclei are present. (D) Quantification of emerin staining using the 0 to 3 grading system. N = 183 total samples #P < 0.02 compared to all non-cancerous tissue, *P < 0.0062 compared to both normal and benign tissue, one-way ANOVA and Dunnett’s test. Error bars represent standard deviation.

Article Snippet: Reduced emerin expression at the nuclear periphery correlates with breast cancer invasiveness in patients. (A) Representative tissue microarray staining of emerin in 159 patients using emerin polyclonal antibodies (Proteintech, cat# 10351-1-AP) or secondary alone (Vector Lab, cat#: MP-7451).

Techniques: Expressing, Microarray, Staining, Plasmid Preparation, Standard Deviation, Bioprocessing

Journal: Pathology and Oncology Research

Article Title: Negative correlation between the nuclear size and nuclear Lamina component Lamin A in intraductal papillary mucinous neoplasms of the pancreas

doi: 10.3389/pore.2022.1610684

Figure Lengend Snippet: Primary antibodies used.

Article Snippet: Emerin , CL0201 , Mouse monoclonal , 2 μg/ml , NBP2-52876, Novus Biologicals, Centennial, CO, US.

Techniques: Concentration Assay

Journal: World Journal of Surgical Oncology

Article Title: Collective analysis of the expression and prognosis for LEM-domain proteins in prostate cancer

doi: 10.1186/s12957-022-02640-z

Figure Lengend Snippet: The expressions of ANKLE1, EMD, and LEMD2 and their relationship with clinical parameters of PRAD. A – C ANKLE1, EMD, and LEMD2 levels were increased in prostate cancer tissues compared to normal tissues (RNA-seq data from TCGA PRAD). The number of the normal group is 52, and the number of the tumor group is 499. D – G Higher ANKLE1 expression was associated with age, N stage, T stage, and M stage. H – K Higher EMD expression was associated with age, N stage, T stage, and M stage. L – O Higher LEMD2 expression was associated with age, N stage, T stage, and M stage. Compared with indicated group, * p < 0.05, ** p < 0.01, *** p < 0.001. n.s., no significant difference

Article Snippet: Three-millimeter tumor sections were incubated with commercial polyclonal antibodies against ANKLE1 (Proteintech, 24080-1-AP), EMD (Proteintech, 10351-1-AP), and LEMD2 (Boster, M00714) at 1:200 dilution overnight at 4 °C.

Techniques: RNA Sequencing, Expressing

Journal: World Journal of Surgical Oncology

Article Title: Collective analysis of the expression and prognosis for LEM-domain proteins in prostate cancer

doi: 10.1186/s12957-022-02640-z

Figure Lengend Snippet: The prognostic analysis of ANKLE1, EMD, and LEMD2 in prostate cancer. A – C The progress-free interval of ANKLE1, EMD, and LEMD2 mRNA level in prostate cancer patients (Kaplan-Meier plotter, tumor samples: n =499). D – F The overall survival of ANKLE1, EMD, and LEMD2 mRNA level in prostate cancer patients (Kaplan-Meier plotter, tumor samples: n = 499). G – L Time-dependent survival ROC curve analysis of ANKLE1, EMD, and LEMD2 to predict 3-, 5-, and 10-year survival rates

Article Snippet: Three-millimeter tumor sections were incubated with commercial polyclonal antibodies against ANKLE1 (Proteintech, 24080-1-AP), EMD (Proteintech, 10351-1-AP), and LEMD2 (Boster, M00714) at 1:200 dilution overnight at 4 °C.

Techniques:

Journal: World Journal of Surgical Oncology

Article Title: Collective analysis of the expression and prognosis for LEM-domain proteins in prostate cancer

doi: 10.1186/s12957-022-02640-z

Figure Lengend Snippet: qPCR, WB, and IHC validation of ANKLE1, EMD, and LEMD2 in prostate cancer. A – C The mRNA levels of ANKLE1, EMD, and LEMD2 in human prostate tumor specimens were validated by qPCR. D – I The protein levels of ANKLE1, EMD, and LEMD2 in human prostate tumor specimens were validated by WB and IHC. The data (means ± SEM) shown ( A – C , n = 5; D – I , n = 3) were representative of three separate experiments. Compared with the indicated group, * p < 0.05, ** p < 0.01, *** p < 0.001

Article Snippet: Three-millimeter tumor sections were incubated with commercial polyclonal antibodies against ANKLE1 (Proteintech, 24080-1-AP), EMD (Proteintech, 10351-1-AP), and LEMD2 (Boster, M00714) at 1:200 dilution overnight at 4 °C.

Techniques: Biomarker Discovery

Journal: World Journal of Surgical Oncology

Article Title: Collective analysis of the expression and prognosis for LEM-domain proteins in prostate cancer

doi: 10.1186/s12957-022-02640-z

Figure Lengend Snippet: The co‐expression genes with ANKLE1, EMD, and LEMD2 in prostate adenocarcinoma from the LinkedOmics database. A – C The significantly associated genes with ANKLE1, EMD, and LEMD2 were distinguished by the Pearson test in the prostate adenocarcinoma cohort. D – F KEGG pathways of ANKLE1, EMD, and LEMD2 in prostate adenocarcinoma cohort

Article Snippet: Three-millimeter tumor sections were incubated with commercial polyclonal antibodies against ANKLE1 (Proteintech, 24080-1-AP), EMD (Proteintech, 10351-1-AP), and LEMD2 (Boster, M00714) at 1:200 dilution overnight at 4 °C.

Techniques: Expressing

Journal: World Journal of Surgical Oncology

Article Title: Collective analysis of the expression and prognosis for LEM-domain proteins in prostate cancer

doi: 10.1186/s12957-022-02640-z

Figure Lengend Snippet: A – C The Correlation between ANKLE1, EMD, and LEMD2 expressions and infiltrating immune cells in prostate cancer

Article Snippet: Three-millimeter tumor sections were incubated with commercial polyclonal antibodies against ANKLE1 (Proteintech, 24080-1-AP), EMD (Proteintech, 10351-1-AP), and LEMD2 (Boster, M00714) at 1:200 dilution overnight at 4 °C.

Techniques:

Journal: World Journal of Surgical Oncology

Article Title: Collective analysis of the expression and prognosis for LEM-domain proteins in prostate cancer

doi: 10.1186/s12957-022-02640-z

Figure Lengend Snippet: Associations of ANKLE1, EMD, and LEMD2 expressions with immunomodulators and chemokines from the TISIDB database. A – I Correlations between immunomodulators (including immune inhibitors, immunostimulators, and MHC molecules) and the expression levels of ANKLE1, EMD, and LEMD2. J – L Correlations between chemokines and the expression levels of ANKLE1, EMD, and LEMD2

Article Snippet: Three-millimeter tumor sections were incubated with commercial polyclonal antibodies against ANKLE1 (Proteintech, 24080-1-AP), EMD (Proteintech, 10351-1-AP), and LEMD2 (Boster, M00714) at 1:200 dilution overnight at 4 °C.

Techniques: Expressing

Journal: World Journal of Surgical Oncology

Article Title: Collective analysis of the expression and prognosis for LEM-domain proteins in prostate cancer

doi: 10.1186/s12957-022-02640-z

Figure Lengend Snippet: Comparison of KM survival curves of ANKLE1, EMD, and LEMD2 expressions based on immune cells. A High ANKLE1 levels enriched in resting NK cells had worse OS in PRAD. B High EMD levels enriched in resting NK cells had worse OS in PRAD. C High LEMD2 levels enriched in resting NK cells had worse OS in PRAD

Article Snippet: Three-millimeter tumor sections were incubated with commercial polyclonal antibodies against ANKLE1 (Proteintech, 24080-1-AP), EMD (Proteintech, 10351-1-AP), and LEMD2 (Boster, M00714) at 1:200 dilution overnight at 4 °C.

Techniques: Comparison

Journal: World Journal of Surgical Oncology

Article Title: Collective analysis of the expression and prognosis for LEM-domain proteins in prostate cancer

doi: 10.1186/s12957-022-02640-z

Figure Lengend Snippet: The analysis of mutation, CNV, and methylation for ANKLE1, EMD, and LEMD2 expressions in PRAD. A – C Heat map showing the correlations between ANKLE1, EMD, and LEMD2 mRNA levels and somatic mutations, CNV, and methylation in prostate cancer through the UCSC Xena database

Article Snippet: Three-millimeter tumor sections were incubated with commercial polyclonal antibodies against ANKLE1 (Proteintech, 24080-1-AP), EMD (Proteintech, 10351-1-AP), and LEMD2 (Boster, M00714) at 1:200 dilution overnight at 4 °C.

Techniques: Mutagenesis, Methylation